Review




Structured Review

GenScript corporation elisa based surrogate assay cpasstm
Elisa Based Surrogate Assay Cpasstm, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa based surrogate assay cpasstm/product/GenScript corporation
Average 90 stars, based on 1 article reviews
elisa based surrogate assay cpasstm - by Bioz Stars, 2026-05
90/100 stars

Images



Similar Products

90
GenScript corporation elisa based surrogate assay cpasstm
Elisa Based Surrogate Assay Cpasstm, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa based surrogate assay cpasstm/product/GenScript corporation
Average 90 stars, based on 1 article reviews
elisa based surrogate assay cpasstm - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
GenScript corporation cpasstm elisa-based sars-cov-2 surrogate virus neutralization antibody detection test kit
( a ) The total anti-S antibodies (including IgG) to the <t>SARS-CoV-2</t> spike protein receptor binding domain (RBD) counts. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) Neutralizing antibodies counts. Data were measured at 3 and 5 weeks after first vaccination, and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.
Cpasstm Elisa Based Sars Cov 2 Surrogate Virus Neutralization Antibody Detection Test Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpasstm elisa-based sars-cov-2 surrogate virus neutralization antibody detection test kit/product/GenScript corporation
Average 90 stars, based on 1 article reviews
cpasstm elisa-based sars-cov-2 surrogate virus neutralization antibody detection test kit - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor binding domain (RBD) counts. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) Neutralizing antibodies counts. Data were measured at 3 and 5 weeks after first vaccination, and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.

Journal: Vaccines

Article Title: Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination

doi: 10.3390/vaccines9101145

Figure Lengend Snippet: ( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor binding domain (RBD) counts. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) Neutralizing antibodies counts. Data were measured at 3 and 5 weeks after first vaccination, and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.

Article Snippet: The cPass™ ELISA-based SARS-CoV-2 surrogate virus neutralization antibody detection test kit (GenScript Biotech Corporation, Piscataway, NJ, USA), applies an indirect detection method via assessing antibody-mediated inhibition of SARS-CoV-2 RBD binding to the human host receptor angiotensin-converting enzyme 2.

Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Neutralization

( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor-binding domain (RBD) counts by gender. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) Neutralizing antibodies counts by gender. Data were measured at 3 and 5 weeks after first vaccination, and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.

Journal: Vaccines

Article Title: Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination

doi: 10.3390/vaccines9101145

Figure Lengend Snippet: ( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor-binding domain (RBD) counts by gender. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) Neutralizing antibodies counts by gender. Data were measured at 3 and 5 weeks after first vaccination, and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.

Article Snippet: The cPass™ ELISA-based SARS-CoV-2 surrogate virus neutralization antibody detection test kit (GenScript Biotech Corporation, Piscataway, NJ, USA), applies an indirect detection method via assessing antibody-mediated inhibition of SARS-CoV-2 RBD binding to the human host receptor angiotensin-converting enzyme 2.

Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Neutralization

( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor-binding domain (RBD) counts by age. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) NeuTable 3 and 5 weeks after first vaccination and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.

Journal: Vaccines

Article Title: Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination

doi: 10.3390/vaccines9101145

Figure Lengend Snippet: ( a ) The total anti-S antibodies (including IgG) to the SARS-CoV-2 spike protein receptor-binding domain (RBD) counts by age. Data were measured at 3 and 5 weeks after first vaccination and 4 months after second vaccination. ( b ) NeuTable 3 and 5 weeks after first vaccination and 4 months after second vaccination with an ELISA-based SARS-CoV-2 Surrogate Virus Neutralization Test Kit.

Article Snippet: The cPass™ ELISA-based SARS-CoV-2 surrogate virus neutralization antibody detection test kit (GenScript Biotech Corporation, Piscataway, NJ, USA), applies an indirect detection method via assessing antibody-mediated inhibition of SARS-CoV-2 RBD binding to the human host receptor angiotensin-converting enzyme 2.

Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Neutralization